• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by Check-Cap Ltd.

    5/1/25 4:15:02 PM ET
    $CHEK
    Medical Electronics
    Health Care
    Get the next $CHEK alert in real time by email
    NT 20-F 1 ea0240325-nt20f_checkcap.htm NOTIFICATION OF LATE FILING

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 12b-25

     

     

     

    NOTIFICATION OF LATE FILING

     

    (Check One):   

    ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q

    ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

         
        For Period Ended: December 31, 2024
         
        ☐ Transition Report on Form 10-K
         
        ☐ Transition Report on Form 20-F
         
        ☐ Transition Report on Form 11-K
         
        ☐ Transition Report on Form 10-Q
         
        For the Transition Period Ended:

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

     

    PART I — REGISTRANT INFORMATION

     

    Check-Cap Ltd.

    Full Name of Registrant

     

    Former Name if Applicable

     

    Check-Cap Building 29, Abba Hushi Avenue P.O. Box 1271

    Address of Principal Executive Office (Street and Number)

     

    Isfiya, 3009000, Mount Carmel, Israel

    City, State and Zip Code

     

     

     

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

     

    ☒   (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
      (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Check-Cap Ltd. (the “Company”) has determined that it is unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2024 (the “Form 20-F”) by the prescribed filing date without unreasonable effort or expense. The Company currently anticipates that the Form 20-F will be filed within the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

     

    As disclosed in the Company’s Report on Form 6-K filed with the U.S. Securities and Exchange Commission on April 15, 2025, the Company, on April 6, 2025, appointed RBSM LLP, as the Company’s new independent registered public accounting firm, to replace Fahn Kanne & Co., a member firm within Grant Thornton. RBSM LLP is conducting an audit of the Company’s financial statements for the period ended December 31, 2024.

     

    The Company’s change in independent registered public accounting firm required the Company to commit additional resources to onboarding the new independent registered public accounting firm, including the transfer of supporting documentation, which was previously provided to the Company’s prior auditor. This additional administrative work reduced the resources the Company has available to complete its financial statements and the other disclosures for the Form 20-F. Therefore, the Company needs additional time to complete the Form 20-F.

     

     

     

    PART IV — OTHER INFORMATION

     

    (1)Name and telephone number of person to contact in regard to this notification

     

    David Lontini   +647   892-9516
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    Because the Company has not completed its financial statements due to the reasons stated above, the Company is unable to provide a reasonable estimate of its results of operations for the fiscal year ended December 31, 2024. However, the Company expects to report significant changes to cash, cash equivalents and restricted cash and net loss for the fiscal year ended December 31, 2024, as compared to the fiscal year ended December 31, 2023, partially due to changes in pursuing and executing on its strategic development plan, including the previously announced business combination transactions.

     

    Cautionary Note Regarding Forward-Looking Statements

     

    This Form 12b-25 includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties, including statements regarding the Company’s expectation that it will timely file its Form 20-F by the extended filing date pursuant to Rule 12b-25. Forward looking statements are based on current expectations but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including but not limited to risks and uncertainties related to the Company’s resources, business and prospects. There can be no assurance that these forward-looking statements will be achieved, and actual results could differ materially from those suggested by such forward-looking statements.

     

    2

     

     

    Check-Cap Ltd.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 1, 2025   By:

    /s/ Alan Lewis

            Alan Lewis
            Chief Financial Officer

     

     

    3

     

    Get the next $CHEK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHEK

    DatePrice TargetRatingAnalyst
    8/9/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CHEK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MBody AI and Check-Cap Enter into Definitive Merger Agreement

    Merger to Create Combined Company Focused on Embodied AI for the Autonomous Workforce ISFIYA, ISRAEL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- MBody AI ("MBody AI") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Agreement and Plan of Merger (the "Merger"). If the Merger is approved by Check-Cap shareholders, it will create a combined company focused on embodied AI for the autonomous workforce. Check-Cap's legacy business will continue its research and development activities as part of the combined company. MBody AI is a market-leading artificial intelligence ("AI") company redefining the future of work through embodied

    9/12/25 5:39:51 PM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap claims BMO's Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime

    Check-Cap Ltd. Issues Strong Condemnation of MediPharm Labs Chairman Chris Taves for Fabricated Defamatory Statements Press Releases Taves Times his Attack to Commence 23 Minutes before the Start of Shabbat to Delay the Company from Responding ISFIYA, ISRAEL, June 04, 2025 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (NASDAQ:CHEK) ("Check-Cap" or the "Company"), a clinical-stage medical diagnostics company incorporated in Israel, today publicly condemned MediPharm Labs Corp. (LABS) ("MediPharm Labs") and its Chairman, Chris Taves, Head of Asia for BMO Capital Markets, for disseminating derogatory, false, and misleading statements about Check-Cap during a profoundly sensitive and challenging time

    6/4/25 7:00:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

    Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion  Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board  Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex

    5/14/25 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

    HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $3.00 from $4.00 previously

    8/9/21 6:35:25 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap downgraded by Dawson James with a new price target

    Dawson James downgraded Check-Cap from Buy to Neutral and set a new price target of $2.00

    3/17/21 12:12:30 PM ET
    $CHEK
    Medical Electronics
    Health Care

    HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

    HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $4.00 from $1.50 previously

    3/16/21 6:31:50 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    SEC Filings

    View All

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    9/12/25 4:38:16 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    9/5/25 4:30:29 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form 20-F filed by Check-Cap Ltd.

    20-F - Check-Cap Ltd (0001610590) (Filer)

    8/26/25 8:59:38 PM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Leadership Updates

    Live Leadership Updates

    View All

    Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting

    Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO, Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, today issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental.  Symetryx discusses its concerns around the actions of the Board in its evaluation

    11/28/23 11:56:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap Appoints Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs

    ISFIYA, Israel, Sept. 1, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs. Dr. Brenner-Lavie will be responsible for leading the Company's overall clinical strategy and implementation as well as driving the Company's clinical direction, including innovation. "Dr. Brenner-Lavie has a proven track record of clinical strategy dev

    9/1/21 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Financials

    Live finance-specific insights

    View All

    Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

    Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion  Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board  Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex

    5/14/25 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Keystone Dental Group Granted Patent from USPTO for Nexus IOS Solution

    IRVINE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Osteon Medical, a subsidiary of Keystone Dental Holdings ("Keystone Dental" or the "Company"), today announced the United States Patent and Trademark Office (USPTO) has granted the Company a patent for its innovative Nexus IOS solution. The Nexus iOS Scan Gauge technology allows implant dentists to perform direct full-arch implant scans using an Intraoral Scanner (IOS) with predictable and passive fitting prosthetic outcomes. This technology replaces the traditionally manual impression-taking process through a faster, cost-effective, and accessible workflow. The Nexus iOS Scan Gauge technology is now the only patented elongated body scan

    10/18/23 4:05:00 PM ET
    $CHEK
    Medical Electronics
    Health Care

    Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement

    Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions Keystone 2022 revenues exceeded $60 million The combined company will trade on the NASDAQ with the ticker "KSD" Investor conference call and webcast scheduled for 8:30 a.m. ET on Thursday, August 17th IRVINE, Calif. and BURLINGTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings, Inc. ("Keystone Dental") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Busin

    8/16/23 5:08:47 PM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

    SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

    4/8/24 7:35:32 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form SC 13D filed by Check-Cap Ltd.

    SC 13D - Check-Cap Ltd (0001610590) (Subject)

    4/1/24 9:26:38 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

    SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

    12/18/23 6:07:13 AM ET
    $CHEK
    Medical Electronics
    Health Care